Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021
23 sept. 2021 01h00 HE
|
INNATE PHARMA
Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma...
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
23 sept. 2021 01h00 HE
|
INNATE PHARMA
Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés...
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021
23 sept. 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Présentation de Données Issues de l'Essai COAST Comprenant Monalizumab au Congrès de l'ESMO 2021
17 sept. 2021 07h45 HE
|
INNATE PHARMA
Marseille, France, 17 sept. 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd'hui qu’AstraZeneca (LSE/STO/Nasdaq : AZN)...
Monalizumab Data From COAST Trial Presented at ESMO Congress 2021
17 sept. 2021 07h45 HE
|
INNATE PHARMA
Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...
Monalizumab Data from COAST Trial Presented at ESMO Congress 2021
17 sept. 2021 07h45 HE
|
INNATE PHARMA
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille au premier semestre 2021
15 sept. 2021 01h00 HE
|
INNATE PHARMA
Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- Les premières données cliniques de TELLOMAK ont établi un taux de réponse global encourageant de 35% avec lacutamab, ainsi qu’une amélioration au niveau...
Innate Pharma reports first half 2021 financial results and business update
15 sept. 2021 01h00 HE
|
INNATE PHARMA
Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with...
Innate Pharma Reports First Half 2021 Financial Results and Business Update
15 sept. 2021 01h00 HE
|
INNATE PHARMA
First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2New...
Rapport Financier Semestriel 30 juin 2021
15 sept. 2021 01h00 HE
|
INNATE PHARMA
Marseille, 15 sept. 2021 (GLOBE NEWSWIRE) -- RAPPORT FINANCIER SEMESTRIEL30 JUIN 2021 INNATE PHARMA S.A.Société anonyme à Directoire et Conseil de surveillanceau capital social de 3 952 095,85...